💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Denileukin Diftitox

CHEMBL1201550 Phase 4 ได้รับการอนุมัติ Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A fusion protein combining interleukin-2 with diphtheria toxin that selectively kills cells expressing high levels of the IL-2 receptor, used for cutaneous T-cell lymphoma. Cancer cells that display IL-2 receptors bind the drug and are killed by the toxin portion.

ด้านการรักษา

Melanoma Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

กลไกการออกฤทธิ์

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A fusion protein combining interleukin-2 with diphtheria toxin that selectively kills cells expressing high levels of the IL-2 receptor, used for cutaneous T-cell lymphoma. Cancer cells that display IL-2 receptors bind the drug and are killed by the toxin portion.

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Yes, Denileukin Diftitox is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201550. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.